GH Research (NASDAQ:GHRS) Trading Down 0.9% - Should You Sell?

GH Research PLC (NASDAQ:GHRS - Get Free Report)'s stock price traded down 0.9% on Thursday . The stock traded as low as $8.64 and last traded at $8.64. 12,976 shares were traded during trading, a decline of 84% from the average session volume of 79,088 shares. The stock had previously closed at $8.72.

Analyst Upgrades and Downgrades

GHRS has been the subject of a number of research analyst reports. HC Wainwright reissued a "buy" rating and set a $40.00 price target on shares of GH Research in a report on Thursday, September 5th. JMP Securities reiterated a "market outperform" rating and issued a $39.00 price target on shares of GH Research in a report on Wednesday, September 4th.

GH Research Stock Performance

The business's 50-day moving average price is $7.85 and its 200 day moving average price is $10.47. The stock has a market capitalization of $451.60 million, a PE ratio of -12.90 and a beta of 0.74.

GH Research (NASDAQ:GHRS - Get Free Report) last announced its earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.03. As a group, equities research analysts predict that GH Research PLC will post -0.85 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in GH Research stock. Lynx1 Capital Management LP lifted its stake in GH Research PLC (NASDAQ:GHRS - Free Report) by 19.8% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,966,726 shares of the company's stock after purchasing an additional 656,163 shares during the quarter. GH Research comprises approximately 16.7% of Lynx1 Capital Management LP's holdings, making the stock its 3rd largest position. Lynx1 Capital Management LP owned 7.62% of GH Research worth $46,252,000 as of its most recent SEC filing. Institutional investors own 56.90% of the company's stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.